ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA Priority Review for supplemental Biologics License Application for Reblozyl® in Adults with Beta Thalassemia
December 06, 2021Bristol Myers Squibb announced that the FDA has accepted for priority review the supplemental Biologics License Application (sBLA) for Reblozyl® (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adults...
Pharma Sources Insight January 2025
